This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Zilver PTX Drug-Eluting Peripheral Stent Study

This study has been completed.
Information provided by (Responsible Party):
Cook Identifier:
First received: April 29, 2011
Last updated: December 29, 2015
Last verified: March 2014
This randomized, post-market clinical study is intended to evaluate the delivery and deployment of longer Zilver PTX stents (≥ 100 mm) compared to shorter Zilver PTX stents (≤80 mm) for treatment of lesions of the above-the-knee femoropopliteal artery.

Condition Intervention
Peripheral Arterial Disease Device: Longer Zilver PTX Stents Device: Shorter Zilver PTX Stents

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Zilver PTX Drug-Eluting Peripheral Stent

Further study details as provided by Cook:

Primary Outcome Measures:
  • Percent Change in Stent Length Upon Deployment [ Time Frame: During Procedure (day 1) (Prior to Stent Deployment and after Stent Deployment) ]

Enrollment: 45
Study Start Date: May 2011
Study Completion Date: September 2012
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Longer Stents Device: Longer Zilver PTX Stents
Treatment with at least one 100 mm or longer Zilver PTX stent
Experimental: Shorter Stents Device: Shorter Zilver PTX Stents
Treatment with Zilver PTX stents 80 mm or shorter only


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • One de novo or restenosed artherosclerotic lesion with > 50% diameter stenosis
  • Reference vessel diameter of 4 - 9 mm
  • Rutherford category ≥ 2
  • Resting ankle brachial index < 0.9

Exclusion Criteria:

  • Prior stent in the study vessel
  • Significant stenosis (> 50%) or occlusion of inflow tract not successfully treated before the study procedure
  • Lacks at least one patent runoff vessel
  • Lesions requiring atherectomy, cutting balloons, cryoplasty balloons, or any other advanced device to facilitate stent delivery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01348425

Bad Krozingen, Germany, 79189
Evangelische Krankenhaus Königin Elisabeth Herzberge
Berlin, Germany, 10365
Universitätsklinikum Magdeburg A.ö.R.
Magdeburg, Germany, 39120
INSELSPITAL, Universitätsspital Bern
Berne, Switzerland, 3010
Sponsors and Collaborators
Principal Investigator: Prof. Dr. med. Jens Ricke Universitätsklinikum Magdeburg A.ö.R., Department for Radiology and Nuclear Medicine
  More Information

Responsible Party: Cook Identifier: NCT01348425     History of Changes
Other Study ID Numbers: 11-003
Study First Received: April 29, 2011
Results First Received: July 25, 2013
Last Updated: December 29, 2015

Keywords provided by Cook:

Additional relevant MeSH terms:
Peripheral Arterial Disease
Peripheral Vascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases processed this record on June 23, 2017